Inventiva to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026 Daix (France), New York (United States), February 4, 2025 – (Euronext Paris and NASDAQ: ) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), today announced that CEO Andrew Obenshain has been invited to participate in a fireside chat at the upcoming Guggenheim Emerging Outlook: Biotech Summit 2026. The conference is being held February 11-12, 2026 at the Lotte New Yor...
Inventiva présentera au Guggenheim Emerging Outlook : Biotech Summit 2026 Daix (France), New York (États-Unis), le 4 février 2026 – Inventiva (Euronext Paris et Nasdaq : IVA) (« Inventiva » ou la « Société »), société biopharmaceutique spécialisée dans le développement de thérapies orales pour le traitement de la stéatohépatite associée à un dysfonctionnement métabolique (« MASH »), a annoncé aujourd’hui que son Directeur général, Andrew Obenshain, a été invité à participer à un « fireside chat » lors du prochain Guggenheim Emerging Outlook: Biotech Summit 2026. La conférence se tiendra le...
Monitoring for a Pullback We maintain our near-term bullish outlook on the S&P 500 (SPX), Nasdaq 100 (QQQ), and Russell 2000 (IWM), which has remained in place since 4/22/25, aside from one week (11/19/25-11/25/25) when we went to neutral. We will stay near-term bullish as long as crucial support levels of 6824 on SPX, $610 on QQQ, and $257 on IWM (up from $245) continue to hold. We continue to see deterioration in market dynamics, and while we expect a period of consolidation/pullback, the afo...
Eurocommercial Properties: 19% stock dividend take up, refinancing completion and leasing update; Ontex: 2H25 consensus release; Signify: 4Q25 results; prepare for a reset; Staffing Sector: Manpower; 4Q25 beat on better revenue trends, 1Q26 outlook positive; WDP: 2030 ambitions revealed, Italy and Spain to come
ABN AMRO appoints Michiel Lap as Chair and nominates Jean-Pierre Mustier as new member of its Supervisory Board ABN AMRO appoints Michiel Lap as Chair and nominates Jean-Pierre Mustier as new member of its Supervisory Board 29 January 2026 Today, ABN AMRO announces that its Supervisory Board will appoint Michiel Lap as Chair of the Supervisory Board of ABN AMRO Bank N.V. with effect from the closure of the Annual General Meeting on 22 April 2026. Michiel Lap will succeed Tom de Swaan, who will retire as Chair after almost eight years. Furthermore, ABN AMRO is pleased to announce the nomin...
ABN AMRO benoemt Michiel Lap als voorzitter en draagt Jean-Pierre Mustier voor als nieuw lid van de Raad van Commissarissen ABN AMRO benoemt Michiel Lap als voorzitter en draagt Jean-Pierre Mustier voor als nieuw lid van de Raad van Commissarissen 29 januari 2026 Vandaag maakt ABN AMRO bekend dat de Raad van Commissarissen Michiel Lap benoemt als voorzitter van de Raad van Commissarissen van ABN AMRO Bank N.V., met ingang van het einde van de Algemene Vergadering op 22 april 2026. Michiel Lap volgt Tom de Swaan op, die na bijna acht jaar terugtreedt als voorzitter. Daarnaast kondigt ABN A...
Half-Year Review of Inventiva’s Liquidity Contract with Kepler Cheuvreux Daix (France), New York City (New York, United States), January 26, 2026 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of patients with metabolic dysfunction-associated steatohepatitis (“MASH”), today announced the half-year report of its liquidity contract with Kepler Cheuvreux. Under the liquidity contract granted to Kepler Cheuvreux by Inventiva, the following resou...
Bilan semestriel du contrat de liquidité de la société Inventiva conclu avec Kepler Cheuvreux Daix (France), New York City (New York, Etats-Unis), le 26 janvier 2026 – Inventiva (Euronext Paris and Nasdaq: IVA) (la "Société"), société biopharmaceutique spécialisée dans le développement de thérapies orales pour le traitement de la stéatohépatite associée à un dysfonctionnement métabolique ("MASH"), annonce aujourd’hui le bilan semestriel de son contrat de liquidité conclu avec Kepler Cheuvreux. Au titre du contrat de liquidité portant sur les actions de la Société confié à Kepler Cheuvreux,...
ABN AMRO: Pre-close 4Q: positive read, but with recent CMD, no surprises on guidance / Ahold Delhaize: New US distribution centre to be leased from Blackstone / Kinepolis: Peer Cineplex December 2025 box office revenue at 89% of 2019 level, up 3% YoY / Randstad: Preview 4Q25F results due 11 February; consensus released / Staffing sector: Hays' 2Q26 trading update; miss vs consensus / Zabka: Peer Biedronka FY25 sales.
BE Semiconductor Industries: Exceptional order intake supports strong FY26. Heineken: Back from the Brink. Wolters Kluwer: An acquisition and a new CP & ESG CEO. Staffing sector: US temp volume touch weaker vs November; downward revisions to Oct/Nov; NFP jobs miss expectations. Coverage change
We hosted our 29th ODDO BHF Forum in Lyon on 8 and 9 January 2026. In total, 220 companies presented over the two days. In the following note, we provide some initial feedback from the companies on Day 2, in addition to Day 1 feedback (Link to Day 1 feedback). Key positive companies were Corbion, DEME, Elia Group, Knorr Bremse, Sulzer, Séché Environnement, Fraport, Vallourec and TUI. More cautious companies were Arkema, Fastned, INWIT, Manitou, Roche Bobois, Téléperformance, and Colonial SFL. T...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.